After 18 months of consolidation and change, FCB Health has appointed Joe Soto and Steven Hebert as the new co-managing directors for its New Jersey office, …
There’s a new spokescharacter lurking around for Prevacid24. The animated ball of fire with a mischievous glint in his eye is the Lurker.
Learn why pharma companies must invest in digital technologies and how those that do can grow market share and revenue.
Drugmakers have joined with governments and nonprofits around the world to launch an alliance that’ll take a proactive approach to potential deadly outbreaks.
There’s a new competitor to Allergan and Ironwood’s Linzess on the block in the chronic idiopathic constipation market.
After losing out to rival Merck on the first-line lung cancer monotherapy front, Bristol-Myers Squibb is now falling further behind with its one-two punch, too.
A top U.S. health official says there’s no settlement with Mylan, adding yet another twist to the company’s prolonged EpiPen episode.
Eli Lilly was so optimistic about its experimental Alzheimer’s treatment, solanezumab, the company staffed up in anticipation of its approval—a move that has…
Sanofi’s Olivier Brandicourt has said acquisitions will help the French drugmaker grow, but the CEO has been unable to pull off a major deal.
In this week's FiercePharmaAsia wrap-up, Astellas terminated an unfruitful vaccine deal, Takeda made a rare disease R&D pact, China's Sanpower…
A new Harris Poll found that only 9% of Americans believe that pharma and biotech companies put patients before profits.